ImmuPharma (LON:IMM) Stock Price Up 15% - What's Next?

Key Points

• ImmuPharma plc shares surged 15% on Wednesday, reaching a last trade price of GBX 13 ($0.18), transitioning from a previous close of GBX 11.30 ($0.15).
• The company has a market capitalization of £64.96 million and reported a quarterly loss with a net margin of 3,519.56% and a negative return on equity of 131.41%.
• ImmuPharma is developing innovative peptide-based therapeutics, including a lead program for treating Lupus, known as Lupuzor™, with potential applications for other autoimmune diseases.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) shot up 15% on Wednesday . The stock traded as high as GBX 13.85 ($0.19) and last traded at GBX 13 ($0.18). 13,221,054 shares changed hands during mid-day trading, an increase of 53% from the average session volume of 8,639,387 shares. The stock had previously closed at GBX 11.30 ($0.15).

ImmuPharma Stock Up 15.0%

The firm has a market capitalization of £64.96 million, a PE ratio of -1,460.67 and a beta of 1.53. The firm's 50 day moving average price is GBX 5.71 and its two-hundred day moving average price is GBX 3.70.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.